Article
Portfolio includes five investigational gene therapy programs for glycogen storage disorders that have no existing FDA-approved treatments available Warden Bio Co-Founder Kunal Kishnani joins as President of Kriya’s Rare Disease Division and will lead its overall strategic, development, and partnership activities Excerpt from the Press Release: REDWOOD CITY, Calif. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Kriya…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., Jan. 6, 2022 /PRNewswire/ — BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced the closeout of the first of two cohorts in its ongoing Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s disease. The purpose of the Ph1 clinical trial…
Read More
ARROS-1 trial enrolling patients with advanced ROS1-positive NSCLC and other solid tumors Clinical development for parallel lead program, NVL-655, in ALK-positive cancers expected to begin in first half of 2022 Excerpt from the Press Release: CAMBRIDGE, Mass., Jan. 7, 2022 /PRNewswire/ — Nuvalent, Inc. (Nasdaq: NUVL), a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in…
Read More
Clear Creek Bio signed a CRADA with the NIH to support its SARS-CoV-2 PLpro inhibitor discovery This CRADA was initiated as part of the Antiviral Program for Pandemics (APP) Via APP, Clear Creek will be able to use the NIH’s current and expanded contract resources and NCATS laboratories to prioritize the advancement of antiviral candidates…
Read More
Excerpt from the Press Release: – 33% Objective Response Rate (ORR) was observed in 33 RECIST evaluable patients across all FolRα expression levels and both dose levels. – Dose response was observed, with a 47% ORR in 17 patients who started at the 5.2 mg/kg dose level. – Tumor proportion score (TPS) was selected as…
Read More
Immunology portfolio highlighted by success of a second positive study with AVTX-002 further validates the LIGHT mechanism of action in inflammatory diseases Efficacy signal demonstrated in heavily pre-treated subjects support further evaluation in inflammatory bowel disease patients’ refractory to three or more treatments, including anti-TNF alpha and other biologics Expands AVTX-002 target indications to include…
Read More
First patient randomized in pivotal phase III study evaluating radiotherapy-activated NBTXR3 with or without cetuximab in high-risk elderly patients with locally advanced head and neck squamous cell carcinoma The randomized study is designed to demonstrate treatment outcome superiority of radiotherapy-activated NBTXR3 versus the standard of care for global registration The US Food and Drug Administration…
Read More
Excerpt from the Press Release: By Celine Zadorsky Sepsis is a life-threatening condition that occurs when the body’s response to an infection triggers excessive inflammation. The inflammatory response can cause damage to organs such as the heart, liver, lungs and brain. While there are currently limited treatments for sepsis, researchers at Lawson Health Research Institute…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Jan. 4, 2022 /PRNewswire/ — Harbour BioMed (“HBM”, HKEX: 02142) announced that, its next generation anti-CTLA-4 fully human heavy-chain only antibody (HCAb), HBM4003, has completed the first dosing of first patient in two phase I trials for the treatment of advanced hepatocellular…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) — TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, and Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced…
Read More